Brief: Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47
06/11/2025 12:00
Nov 06 (Reuters) - Amylyx Pharmaceuticals Q3 operating income USD -36.027 million vs. IBES estimate USD -43.1 million. Q3 pretax profit USD -34.386 million vs. IBES estimate USD -42.5 million Q3 operating expenses USD 36.027 million Q3 net income USD -34.386 million vs. IBES estimate USD -41.6 million
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock